There is an increased risk of DIC and venous thromboembolism.
The use of Low Molecular Weight Heparin in the management of COVID-19 patients is recommended to improve prognosis and for overall reduction in mortality.
In the retrospective study, the 28 day mortality between LMWH users and nonusers were compared, also in different risk of coagulopathy which was stratified by the sepsis‐induced coagulopathy (SIC) score or D‐dimer result.
Results of the study –
No of patients enrolled – 449 COVID-19 patients
No of patients who received Heparin (LMWH mostly) – 99
Duration of LMWH administration – > = 7 Days
28 Day Mortality of Heparin Users were lower than Non Users in patients with SIC (Sepsis Induced Coagulopathy) score >= 4 and D – Dimer > 6 fold the Upper Limit of Normal
Administering LMWH appears to be associated with better disease prognosis in Severe COVID-19 Patients meeting SIC Criteria and Elevated D-dimer levels.
Reference Link : https://onlinelibrary.wiley.com/doi/10.1111/jth.14817